Avivagen Inc. (OTCMKTS:VIVXF – Get Rating) – Investment analysts at Zacks Small Cap reduced their FY2022 EPS estimates for shares of Avivagen in a note issued to investors on Wednesday, August 31st. Zacks Small Cap analyst D. Bautz now anticipates that the company will earn ($0.08) per share for the year, down from their prior estimate of ($0.07). The consensus estimate for Avivagen's current full-year earnings is ($0.07) per share.Get Avivagen alerts:
Avivagen (OTCMKTS:VIVXF – Get Rating) last announced its quarterly earnings results on Wednesday, June 15th. The company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02). The company had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.23 million.
Avivagen Price PerformanceShares of OTCMKTS:VIVXF opened at $0.13 on Friday. The company's 50 day moving average price is $0.14 and its two-hundred day moving average price is $0.15. Avivagen has a 12-month low of $0.12 and a 12-month high of $0.38. The firm has a market cap of $9.33 million, a PE ratio of -1.40 and a beta of 0.13.
Avivagen Inc, a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr.
- Get a free copy of the StockNews.com research report on Avivagen (VIVXF)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Avivagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avivagen and related companies with MarketBeat.com's FREE daily email newsletter.